The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and ...

Pfizer’s non-COVID operational revenues have been driving its top-line growth, backed by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products from ...

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple ...

To provide the right treatment for multiple sclerosis (MS), it is important to know when the disease changes from ...

Immunic (IMUX) stock sees a drop of 22% after Phase 2 trial data for its multiple sclerosis drug vidofludimus calcium. Read ...